Global OAB Treatment Market Strategic Research Report

Scope of the Report

The global OAB Treatment market size is predicted to grow from US$ 5,295 million in 2025 to US$ 5,844 million in 2032; it is expected to grow at a CAGR of 1.4% from 2026 to 2032.

Overactive bladder (OAB) is a common disease characterized by urinary urgency, often accompanied by frequent urination and nocturia, with or without urge urinary incontinence. This report focuses on the OAB treatment drug market, which is divided into: anticholinergic drugs, Mirabegron, Botox and others by drug type.

Overactive bladder (OAB) is a common disease, and the incidence of OAB shows an upward trend with age. With the continuous increase in the global elderly population, the number of elderly OAB patients has shown an upward trend year by year, which has attracted further attention from governments and the pharmaceutical treatment market. The OAB treatment drug market has great potential. The introduction of pharmaceutical industry policies, the policy changes and market environment, and the policy trends and future market development trends, although there are challenges, are actually evolving in a direction that is beneficial to innovative enterprises, which is conducive to promoting the long-term standardized development of the industry and providing good opportunities for OAB new drug companies with high-level R&D, production and quality management systems. It will be conducive to promoting the development of the OAB treatment drug industry. With the continuous advancement of technology and the innovation of new instruments, the surge in the number of new drugs discovered, the increase in government funds and the undeveloped emerging markets will further generate profitable markets, thereby promoting the market growth of OAB drugs. With the continuous increase in global healthcare infrastructure spending, the increase in per capita disposable income and the expansion of medical insurance coverage, residents' ability to pay for medical care has increased, driving the development of the OAB drug industry.

This report presents a comprehensive overview of the global OAB Treatment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Anticholinergics
• Mirabegron
• Botox
• Others

Segment by players, this report covers

• AbbVie
• Astellas Pharma
• Pfizer
• Teva
• Johnson & Johnson
• Kyorin Pharmaceutical

Segment by Application

• Idiopathic Overactive Bladder
• Neurogenic Overactive Bladder

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global OAB Treatment market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Idiopathic Overactive Bladder, Neurogenic Overactive Bladder evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact